Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans

What Was Tested

The paper reports a study of Glucagon, published as a controlled clinical trial.

The purpose of this study was to determine whether an extended infusion of the incretin hormone glucagon-like peptide 1 (GLP-1) has a greater effect to promote insulin secretion in type 2 diabetic subjects than acute administration of the peptide.

Who Took Part

The study group was 2 subjects.

By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.

First-phase insulin release (FPIR; the incremental insulin response in the first 10 min after the intravenous glucose bolus) and second-phase insulin release (SPIR; the incremental insulin response from 10-60 min after intravenous glucose) were measured during three separate intravenous glucose tolerance tests (IVGTTs): 1). without GLP-1 (control); 2). with acute administration of GLP-1 as a square wave starting just before glucose administration; and 3). with an extended infusion of GLP-1 for 3 h before and during the IVGTT.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Insulin, Insulin Secretion and Islets of Langerhans.

What This Means in Plain Language

This is a controlled clinical trial of Glucagon in 2 subjects.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2003 (Diabetes care), a journal based in United States.

More context: the Glucagon compound page, all human trials.